What is the price target for PSTV stock?
11 analysts have analysed PSTV and the average price target is 140.15 USD. This implies a price increase of 2023.45% is expected in the next year compared to the current price of 6.6.
NASDAQ:PSTV • US72941H5090
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PLUS THERAPEUTICS INC (PSTV).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-09 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2026-03-31 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2026-03-19 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-23 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-08 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-11 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-01 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-11-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-11-03 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-31 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-21 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-10-06 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-09-25 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-22 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-18 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-09-03 | D. Boral Capital | Upgrade | Hold -> Buy |
| 2025-08-18 | Maxim Group | Maintains | Buy -> Buy |
| 2025-06-27 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-06-25 | D. Boral Capital | Maintains | Hold -> Hold |
| 2025-06-05 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-05-05 | D. Boral Capital | Downgrade | Buy -> Hold |
| 2025-04-21 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-03-28 | D. Boral Capital | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 4.913M 2,133.18% | 5.824M 18.54% | 5.213M -10.49% | 5.901M 13.20% | 21.331M 261.48% | 48.687M 128.25% | 135.29M 177.88% | 187.93M 38.91% | 336.7M 79.16% | 754.94M 124.22% | 1.117B 47.96% | |
| EBITDA YoY % growth | -12.693M 33.51% | -13.972M -10.08% | -14.853M -6.31% | -15.096M -1.64% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -13.321M 32.42% | -14.695M -10.31% | -15.298M -4.10% | -24.616M -60.91% | -17.032M 30.81% | -6.745M 60.40% | 58.083M 961.09% | 97.595M 68.03% | 212.76M 118.00% | 564.83M 165.48% | 875.94M 55.08% | |
| Operating Margin | -271.14% | -252.32% | -293.46% | -417.14% | -79.85% | -13.85% | 42.93% | 51.93% | 63.19% | 74.82% | 78.42% | |
| EPS YoY % growth | -113.25 53.54% | -54.25 52.10% | -31.29 42.33% | -3.70 88.18% | -2.17 41.38% | -0.77 64.71% | 0.19 125.33% | 0.35 78.95% | 0.84 141.18% | 1.96 134.15% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.90 96.99% | -0.84 -268.91% | -0.84 15.54% | -0.80 23.30% | -0.76 15.15% | -0.76 10.02% | -0.69 18.48% | -0.69 13.46% |
| Revenue Q2Q % growth | 993.48K -6.19% | 1.263M -9.14% | 1.553M 11.17% | 2.087M 52.67% | 3.66M 268.40% | 3.775M 198.89% | 4.514M 190.66% | 4.629M 121.80% |
| EBITDA Q2Q % growth | -5.304M -56.46% | -5.304M -303.35% | -5.304M -26.83% | -5.304M -0.13% | -4.284M 19.23% | -4.284M 19.23% | -3.264M 38.46% | -3.264M 38.46% |
| EBIT Q2Q % growth | -5.475M -54.82% | -5.504M -257.90% | -5.457M -21.75% | -5.199M 9.46% | -4.815M 12.04% | -4.914M 10.73% | -4.601M 15.69% | -4.7M 9.60% |
All data in USD
11 analysts have analysed PSTV and the average price target is 140.15 USD. This implies a price increase of 2023.45% is expected in the next year compared to the current price of 6.6.
PLUS THERAPEUTICS INC (PSTV) will report earnings on 2026-05-28.
The consensus EPS estimate for the next earnings of PLUS THERAPEUTICS INC (PSTV) is -0.9 USD and the consensus revenue estimate is 993.48K USD.
The consensus rating for PLUS THERAPEUTICS INC (PSTV) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.